Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234409 | 1.00 | ALDH1A1 (0.35) | ALDH1A1ACETSHR | |
| SCHEMBL18528415 | 0.91 | TSHR (0.34) | ALDH1A1ACETSHR | |
| SCHEMBL18528413 | 0.91 | TSHR (0.34) | ALDH1A1ACETSHR | |
| SCHEMBL23586831 | 0.86 | ALDH1A1 (0.33) | ALDH1A1ACE | |
| SCHEMBL18528431 | 0.85 | ALDH1A1 (0.33) | ALDH1A1ACE | |
| SCHEMBL18528433 | 0.85 | ALDH1A1 (0.33) | ALDH1A1ACE | |
| SCHEMBL17234403 | 0.85 | ALDH1A1 (0.33) | ALDH1A1ACE | |
| SCHEMBL18528392 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL17234408 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL17234406 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | ALDH1A1 1159/4885ACE 1330/4885TSHR 4530/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ALDH1A1 2023/4885ACE 704/4885TSHR 4268/4885 |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ALDH1A1 2023/4885ACE 704/4885TSHR 4268/4885 |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ALDH1A1 2023/4885ACE 704/4885TSHR 4268/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ALDH1A1 2023/4885ACE 704/4885TSHR 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.